Concordia Healthcare (NASDAQ: CXRX) recently received a number of ratings updates from brokerages and research firms:

  • 11/30/2015 – Concordia Healthcare is now covered by analysts at CIBC. They set a “sector perform” rating and a $47.00 price target on the stock.
  • 11/16/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at Canaccord Genuity.
  • 11/10/2015 – Concordia Healthcare was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Concordia Healthcare Corp. operates as a healthcare business which includes the management and acquisition of legacy pharmaceutical products and acquires and develops orphan drugs. The company’s operating segment consists of Legacy Pharmaceuticals, Specialty Healthcare Distribution and Orphan Drugs. Concordia Healthcare Corp. is headquartered in Oakville, Canada. “
  • 11/10/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $55.00 price target on the stock.
  • 10/27/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at Canaccord
    • 10/26/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at Dundee Securities.
    • 10/22/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at TD Securities. They now have a $60.00 price target on the stock, down previously from $105.00.
    • 10/22/2015 – Concordia Healthcare had its price target lowered by analysts at RBC Capital from $86.00 to $77.00. They now have an “outperform” rating on the stock.
    • 10/19/2015 – Concordia Healthcare was upgraded by analysts at Mackie from a “hold” rating to a “speculative buy” rating. They now have a $42.50 price target on the stock, down previously from $81.00.
    • 10/16/2015 – Concordia Healthcare had its “sector outperform” rating reaffirmed by analysts at Scotiabank. They now have a $75.00 price target on the stock, down previously from $80.00.
    • 10/16/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at S&P Equity Research. They now have a $60.00 price target on the stock.
    • 10/9/2015 – Concordia Healthcare had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $55.00 price target on the stock.
    • 10/7/2015 – Concordia Healthcare was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $44.00 price target on the stock. According to Zacks, “Concordia Healthcare Corp. operates as a healthcare business which includes the management and acquisition of legacy pharmaceutical products and acquires and develops orphan drugs. The company’s operating segment consists of Legacy
    • Pharmaceuticals, Specialty Healthcare Distribution and Orphan Drugs. Concordia Healthcare Corp. is headquartered in Oakville, Canada. “

      Shares of Concordia Healthcare (NASDAQ:CXRX) traded up 2.73% during midday trading on Tuesday, reaching $39.57. The company had a trading volume of 227,208 shares. The company’s 50-day moving average is $32.41 and its 200-day moving average is $60.98. Concordia Healthcare has a 1-year low of $19.02 and a 1-year high of $89.10. The stock has a market capitalization of $2.01 billion and a PE ratio of 282.64.